4D Molecular Therapeutics (FDMT) investor relations material

Platform and pipeline overview

• Utilizes directed evolution to create customized gene therapy vectors for targeted tissue delivery, aiming for improved safety and lower costs.

• Lead product 4D-150 targets wet AMD and diabetic eye disease, currently in two phase 3 trials with strong enrollment.

• 4D-710, an aerosol gene therapy for cystic fibrosis, has shown high gene expression and is advancing through phase 2.

Clinical data and unmet needs

• 4D-150 demonstrated over 97% of patients with no inflammation or toxicity at phase 3 dose, with robust safety profile.

• Achieved up to 94% reduction in injection burden for wet AMD, with 80% of patients injection-free at one year in certain populations.

• Consistent dose response and efficacy observed across diverse patient groups in both wet AMD and DME.

• Key unmet needs include extended durability and maintaining vision gains over time.

Physician and market perspectives

• Retina specialists prioritize safety and durability; recent survey shows 50% most excited about gene therapy for new treatments.

• 4D-150’s workflow integration is seamless, matching current anti-VEGF practices and minimizing disruption.

• Steroid regimen for prophylaxis is well tolerated, accessible, and accepted by patients and practitioners.